Overview

Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugen utilizes a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates.  Selected product candidates are then advanced in its Pipeline Program to the pre-IND stage. The Company's business model primarily involves collaborations covering the further development and commercialization of product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen-discovered drug targets. In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA) - to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology.
For additional information, please visit Evogene’s corporate Website at www.evogene.com

Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.

Investor Relations
If you would like more information about Compugen's investor relations activities or would like be added to our investors mailing list, please contact:

Ari Krashin
Chief Financial Officer
Tel: +972-3-765-8595
This email address is being protected from spambots. You need JavaScript enabled to view it.